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Some patients with proteinase 3 specific anti-neutrophil
cytoplasmic autoantibodies (PR3-ANCA) also have antibodies
that react to complementary-PR3 (cPR3), a protein encoded
by the antisense RNA of the PR3 gene. To study whether
patients with anti-cPR3 antibodies have cPR3-responsive
memory T cells we selected conditions that allowed
cultivation of memory cells but not naı¨ve cells. About half of
the patients were found to have CD4þ TH1 memory cells
responsive to the cPR3138-169-peptide; while only a third
of the patients had HI-PR3 protein responsive T cells.
A significant number of T cells from patients responded to
cPR3138-169 peptide and to HI-PR3 protein by proliferation
and/or secretion of IFN-c, compared to healthy controls while
there was no response to scrambled peptide. Cells responsive
to cPR3138-169-peptide were not detected in MPO-ANCA
patients suggesting that this response is specific. The
HLADRB1* 15 allele was significantly overrepresented in our
patient group and is predicted to bind cPR3138-169 peptide
with high affinity. Regression analysis showed a significant
likelihood that anti-cPR3 antibodies and cPR3-specific T cells
coexist in individuals, consistent with an immunological
history of encounter with a PR3-complementary protein.
We suggest that the presence of cells reacting to potential
complementary protein pairs might provide an alternative
mechanism for auto-immune diseases.
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Patients with antibodies reactive with our recombinant
complementary proteinase 3 (cPR3105201) protein must
have experienced an immunological encounter with a cPR3-
like antigen. The following studies are based on the proposal
that T cells involved in this immunological response remain
in a memory cell pool and are identifiable.
Our investigations into complementary proteins in PR3-
anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis
disease began after some unexpected results during experi-
ments designed to determine sites on PR3 protein recognized
by PR3 autoantibodies. To generate bacterial clones expres-
sing different fragments of human PR3 protein, a blunt-
ended ligation strategy was used to clone randomly generated
DNA fragments. Consequently, the DNA fragments could
insert into the vector in either a sense or anti-sense orien-
tation, and thus some bacterial clones were expressing a
protein fragment from anti-sense RNA. Patients’ sera were
found to react to some of these cPR3-producing clones.
Subsequently, a recombinant complementary PR3 protein
was produced in a human cell line, termed cPR3105201,
which is the complement of the middle third of the sense PR3
protein (105–201 aa (amino acids)). Using this reagent, we
proved that anti-cPR3105201-specific antibodies were unique
and that they bound PR3-ANCA to form an idiotypic pair.1
Furthermore, cPR3105201 protein and native PR3 physically
interacted characteristic of a complementary protein pair.
Complementary proteins were first defined in the late
1960s by L.B. Mekler,2,3 who proposed that information
embedded within the genetic code could identify proteins
that would pair in nature, that is, proteins from sense codons
bind proteins from their anti-sense codons. Many researchers
have discovered protein partners by using complementary
sequences coded by anti-sense codons (reviewed by Heal
et al.4 and Tropsha et al.5).
Earlier studies focused on complementary proteins and
their antibody-producing B cells. The present studies focus
on T cells. To date, no one has purposefully searched in
humans for T cells that respond to complementary protein
counterparts of known autoantigens. What has been done in
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PR3-ANCA disease is a search for PR3-specific reactive
T cells. Although a proliferative response was observed, the
results failed to show a disease-specific association.6–12 These
data raise the question of why on the one hand we can
identify disease-associated PR3 autoantibodies,13 but on the
other hand have difficulty identifying disease-associated
T cells.14 As a new approach, investigations into the potential
contributions of complementary proteins could prove
informative. In support, a report published in the year
2000 proposed that difficulties identifying disease-associated
PR3-specific T cells could be explained if a protein
complexed to PR3, and not PR3 itself, was what actually
induced T cell help for PR3-specific B cells.10 Could the
protein suggested to be in complex with PR3 be a ‘comple-
mentary protein’? It has been proposed that complementary
proteins when complexed would have a unique structure that
appears foreign.15,16 However, immunological responses
incited by a complementary protein not complexed to its
sense counterpart must be equally considered at this point.
If patients with PR3-ANCA have experienced an immuno-
logical encounter with a cPR3-like antigen, then the T cells
involved in that encounter may still be present and identi-
fiable. Herein we establish the first human correlate between
T-cell responses and complementary proteins.
RESULTS
Patient study group
Patients with biopsy-proven PR3-ANCA vasculitis (n¼ 30)
were identified through the Glomerular Disease Collaborative
Network between January 2004 and June 2006 (Table 1).
All patients donated a blood sample were included in the
study. However, if a patient’s cells from a particular sample
did not respond to recall antigens (a mixture of tetanus
toxoid, diphtheria toxin, and Candida) was assumed anergic
and was not included in that particular analysis. Thus,
patient enrollment was generally limited to those in remis-
sion, slightly active disease on maintenance drugs, or newly
diagnosed patients before aggressive treatment. Because of
limitations on the amount of blood obtainable per donation,
inclusion in the different analyses required that patients
donate more than once during the study period (Table 1).
Proliferative response of cPR3138169 peptide-reactive T cells
To test for T cells specific for cPR3, a peptide was synthesized
(cPR3138–169) containing 32 amino acids of the original
recombinant protein (cPR3105201). This sequence was
identified in epitope mapping studies as reactive with
patients’ antibodies,1 and later confirmed by mass spectro-
metry (manuscript in review). Control peptides included
scrambled amino acids of cPR3138169 and the sense
counterpart of PR3 (sense PR3138169). A higher number of
CD3þ T cells from patients with PR3-ANCA (Wilcoxon
ranked sum test, P¼ 0.0014), but not patients with
myeloperoxidase (MPO)-ANCA, proliferated upon encoun-
ter with cPR3138169 peptide compared with healthy controls
(Figure 1b). In parallel, patients were tested for T cells that
proliferated in response to heat-inactivated full-length PR3
protein. An increase in proliferating cells was detected,
although the majority of these were from four patients
(P¼ 0.01) (Figure 1c). Cells from patients and healthy
controls responded similarly to recall antigen stimulants
(P¼ 0.79). The percentage of background proliferation
(% of total CD3þ cells that were carboxyfluorescein diacetate
succinimidyl ester (CFSE)dim) was similar comparing
patients (3.0±4.2%) and healthy controls (2.0±2.02%).
Proliferative response to cPR3138169 peptide occurred
without additional co-stimulation with cytokines, suggesting
that these T cells had a memory cell phenotype.17 In support,
KLH peptide, as a stimulant that requires naive cell
proliferation, failed to produce a response using cells from
10 PR3-ANCA patients and 7 MPO-ANCA patients (mean
CDI: recall antigens¼ 6.55±8.9; KLH¼ 1.10±0.49) (repre-
sentative of data—Figure 1d).
T cells produce interferon-c in response to cPR3138169
peptide
A higher number of T cells from patients secreted interferon-g
(IFN-g) when stimulated with cPR3138169 peptide, as
compared with healthy controls (Wilcoxon ranked sum test,
Po0.0001) (Figure 2a). Specificity is supported by a dose-
dependent response seen using cells from three patients versus
healthy controls (Figure 2b). A significant increase in IFN-g-
secreting cells was also seen with exposure to sense PR3138169
peptide (P¼ 0.008) and to heat-inactivated proteinase 3
(HI-PR3) protein (P¼ 0.03) in contrast to scrambled
cPR3138169 peptide (P¼ 0.35) (Figure 2a). There was a
tendency of patients’ T cells to be less responsive to the recall
antigen proteins but not significantly different from healthy
controls (Figure 2c). To determine whether CD4þ or CD8þ
cell was responding to cPR3138169 peptide, IFN-g secretion
was pharmacologically blocked and cells were analyzed by
flow cytometry. A significant increase in CD4þ -IFN-g-
positive cells was found versus positive CD8þ cells (Wilcoxon
ranked sum test, P¼ 0.005) (Figure 2d).
We asked if the complex of peptides, cPR3138–169 with
sense PR3138169, would have a differential effect on stimu-
lating capacity. Eight patients’ T-cell samples were examined
for INF-g secretion in response to complexed peptides versus
individual peptides. KLH peptide was included as a negative
control. Rather than enhancing the INF-g response, mixing
abrogated the cPR3138169 peptide effect (Figure 3).
Compiling the data from the proliferation and cytokine
studies, a statistical analysis of people who respond to the
various stimulants versus those who did not respond was
determined based on the mean plus 2 s.d. of healthy controls
setting Pp0.05 as significant (Table 2). The analysis of the
proliferation data indicated that a significant percentage of
patients (54%) responded to cPR3138169 in contrast to the
percentage of HI-PR3 protein responders (31%), which was
not statistically different from healthy controls. Analysis of
the INF-g data indicated that a significant number of patients
responded to both cPR3138169 and HI-PR3 protein.
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Specificity of responses to fragments of cPR3138169 peptide
cPR3138169 peptide bears some homologies to a number
of bacterial proteins.1 It was questioned whether this
32 aa peptide had characteristics similar to a pathogen-
derived superagonist. Three 16 aa overlapping peptide
fragments were tested for stimulatory characteristics with
the supposition that superantigen-like sequences would
bias reactivity toward one fragment. IFN-g responses were
not restricted to only one sequence within a particular
fragment (Table 3), that is, no superantigen sequences were
Table 1 | Information on patients with PR3-ANCA vasculitis
Patients (n=30) Samples (n=49) Sex Race Age (years) HLA II DRB1 alleles Clinical diagnosis *BVAS score Treatment
A 1a M W 31 03, 10 WG 0 MMF
2b 0 MMF
3c 0 MMF
B 1c M B 50 04, 15 WG 0 AZA, GC
2c 0 AZA, GC
C 1c M W 58 15, 15 CSS 0 AZA
D 1c M W 42 03, 14 MPA 0 MMF
E 1b M W 72 03, 11 WG 0 CYC, GC
F 1c F W 47 03, 15 MPA 0 MMF
2c 0 MMF
G 1a,b M W 69 03, 07 WG 0 CYC, GC
2c,b 0 AZA, GC
H 1a,b F W 66 04, 07 WG 0 GC
I 1b M W 26 NA MPA 0 AZA, GC
2c 0 AZA, GC
J 1a,b M W 38 01, 14 MPA 0 Off therapy
2c 0 Off therapy
3c 0 Off therapy
K 1a M W 57 03, 11 MPA 0 AZA
2c 0 AZA
L 1a M W 64 NA MPA 0 CYC
M 1a,b M B 32 04, 15 WG 0 Off therapy
N 1c M W 26 07, 15 WG 0 Off therapy
O 1c F B 55 15, 15 WG 3 AZA
2b 3 AZA
3c 0 AZA
4c 3 AZA
P 1a M W 34 01, 04 WG 5 GC
2c 1 MMF, GC
Q 1a,c F W 79 11, 13 MPA 2 MMF
2c 0 MMF
3c 0 Off therapy
R 1c M W 59 07, 15 WG 3 CYC
2c 0 Off therapy
S 1b,c F W 56 01, 04 WG 7 AZA, GC
T 1c F W 56 11, 13 WG 6 MMFd
U 1c M Other 31 03, 07 WG 5 MMF
V 1c M W 47 01, 07 WG 3 MMF, GC
W 1c F W 26 01, 07 WG 3 AZA, CsA
X 1a M W 50 04, 12 MPA 3 MMF, CsA, GC
Y 1a F W 63 03, 04 WG 12e CYC, GC
2c 3 AZA, GC
Z 1a F W 59 15, 15 MPA 11e CYC, GC
2c 0 MMF, CsA
3c 0 MMF
AA 1c M W 60 NA MPA 0 MMF
BB 1c M W 37 NA WG 0 MMF
CC 1c F A 52 NA WG 25e CYC, GC
DD 1c F W 66 NA WG 16e GC
A, Asian; AZA, azathioprine; B, Black; CFSE, carboxyfluorescein diacetate succinimidyl ester; CsA, cyclosporine; CSS, Churg–Strauss syndrome; CYC, cyclophosphamide; ELISPOT,
enzyme-linked immunospot assay; F, female; FACS, fluorescence-activated cell sorter; GC, glucocorticoids; HLA, human leukocyte antigen; IFN-g, interferon-g; M, male; MMF,
mycophenolate mofetil; MPA, microscopic polyangiitis; NA, not applicable; PR3-ANCA, proteinase 3-specific anti-neutrophil cytoplasmic autoantibodies; WG, Wegener’s
granulomatosis; W, white.
Assays performed per sample are as follows:
aProliferation by CFSE staining,
bIFN-g levels by FACS, and
cIFN-g secretion by ELISPOT.
dStatus post-rituximab therapy.
eOnset of disease.
*BVAS-Birmingham vasculitis activity score.
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apparent, thus supporting the specificity of responses to
cPR3138169.
Human leukocyte antigen allele frequencies in the patient
group
Differences in the immunogenetic backgrounds of patients, in
particularly human leukocyte antigen (HLA) class II mole-
cules, may account for observed immune responses to
cPR3138169 peptide. Of 48 HLA-DR alleles from 24 patients,
11 were DRB1*15 at a frequency of 0.229. Statistical
comparisons of observed frequencies to the expected frequen-
cies of 0.093 in the general population18 indicated an
overrepresentation of this allele in the patient group (Fisher’s
exact test, P¼ 0.006) (Table 4). There was no statistical
differences for the alleles DQB1*6 (P¼ 0.18), DQB1*5
(P¼ 0.99), DQB1*3 (P¼ 0.57), and DQB1*2 (P¼ 0.26).
To address whether the DRB1*15 protein is a binder of
cPR3138169 peptide, we performed an analysis using the
Immune Epitope and Analysis Resource database.19 HLA II
molecules bind 8-aa fragments, and therefore the various
alleles might preferentially bind different regions of the 32 aa
cPR3138169 peptide. DRB1*01 and DRB1*15 bind with high
affinity (IC50o50) (Table 5). DRB1*03, DRB1*07, DRB1*11,
and DRB1*13 are predicted to bind with intermediate
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Figure 1 | Patients with PR3-ANCA vasculitis harbor T cells that proliferate, when stimulated with complementary (c)PR3138–169
peptide. (a) Representation flow cytometric data; CD3þ T cells were gated and analyzed for the presence of a CFSEdim subset (upper left
quadrant). (b and c) Proliferative response of CD3þ T cells of vasculitis patients with PR3-ANCA, MPO-ANCA, and healthy controls (HC)
after antigen stimulation. Solid horizontal lines indicate mean values. Comparisons between groups were done using the Wilcoxon
ranked sum test.(d) Positive T-cell response to recall antigen coincident with non-responsiveness to KLH indicates responding cells are
memory cells versus naive cells.
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affinity, whereas DRB1*04 is the least likely to bind with a
low affinity for only one region of the fragment.
Individual variability among longitudinal samples
The substantiation of the validity-specific T-cell responses in
the patient group lies in the employment of multiple
methodologies using repetitive patient samplings. A graphical
representation of each patient’s T-cell responsiveness over-
time provides a look at the potential for variable outcomes
(Figure 4a). Patient A was positive in all three assays with
the proliferation studies (2004), fluorescence-activated cell
sorter (FACS) (2005), and enzyme-linked immunospot assay
(ELISPOT) (2006). However, patient K was negative in 2004
for proliferation and positive in 2005 for ELISPOT assay.
Explanations for variability are not obvious, as both patients
were in remission and drug regimens remained consistent.
We asked if disease status could explain, in part, the
variability. Statistical comparisons of patients in remission
(BVAS¼ 0) with those not in remission (BVAS score 40)
indicated an equal distribution within the responsive T-cell
group and the non-responder group (Fisher’s exact test
P¼ 0.99) (Figure 4b). Other potential explanations such as
type of medication (Table 1) or environmental-related factors
were not identifiable. Variability is inevitable and appears to
be a common occurrence in studies of human subjects.10
Coexistence of cPR3-specific T cells with anti-cPR3-specific
antibodies
A critical question concerning the functional consequences of
cPR3138169 peptide-reactive CD4þ TH1 cells is whether
they were involved in cPR3-specific B-cell maturation and
antibody expression. To determine whether the patients
enrolled in the T-cell study were positive anti-cPR3-specific
antibodies, at any point during the course of their disease, all
available-banked sera samples were screened. If a positive
serum sample was identified for an individual, that
individual was considered to have experienced an immuno-
logical response, which could be correlated with the
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Figure 2 | cPR3138–169 peptide stimulates CD4þ T cells to release IFN-c. (a) ANCA vasculitis patients (Pts) and healthy controls
(HC) were analyzed for cytokine secreting T cells by ELISPOT (data indicate fold change of stimulated cells versus unstimulated).
(b) Response to cPR3138–169 peptide was dose-dependent. Three patients (open symbols) and three healthy controls (closed symbols)
were analyzed for IFN-g release after stimulation with varying concentrations of peptide. (c) Responses to recall antigens (mixture
containing tetanus toxoid, diphteria toxin and candida) were similar between groups. (d) FACS analysis intracellular IFN-g levels identified
cPR3138–169 peptide-responsive cells as CD4þ . Comparisons between groups were done using the Wilcoxon ranked sum test.
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production of a memory T-cell pool. The mean value for
patients was 27.96±21.20, compared with healthy controls
at 15.59±5.51 (Wilcoxon ranked sum analysis, P¼ 0.05).
All patients with detectible antibodies were positive for
reactive T cells (Figure 5a). Because availability of sera
samples was limited for some patients, a positive antibody
episode may have been missed, so it is uncertain whether the
remaining patients with positive for T cells ever had the
antibodies. A ranked linear regression analysis indicated
a likelihood of P-value of 0.0086 that, if patients had
cPR3138169 peptide-reactive T cells, they would also have the
reactive antibodies. The data support the conclusion that a
complementary PR3 protein (or its mimic) was presented as
a helper T-cell epitope stimulating B-cell maturation and
antibody production.
DISCUSSION
This is the first report of disease-related T-cell responsiveness
to a protein complementary to a known autoantigen. The
data reveal cPR3138169-responsive T cells of the CD4þ -TH1
class, a T-cell subtype that is capable of delivering signals for
B-cell maturation.20 There was a significant correlation
between the presence of anti-cPR3 antibodies and responsive
T cells on an individual basis. These data are consistent with a
complementary protein-specific component in immuno-
logical events of PR3-ANCA vasculitis autoimmune disease.
Proliferation-based analyses of HI-PR3 protein responsive-
ness were significant when considering cell number, although
the major contribution of positive cells was from only four
patients and 4 of 13 responders did not reach significance,
similar to published results.10 However, HI-PR3 protein-
responsive T cells were found to have a positive correlation
with disease, compared with healthy controls, as assessed
using the IFN-g secretion assay. Nonetheless, the magnitude
of the response was far below that seen in response to
cPR3138169. One explanation for the discordance of data
between assays is that the ELISPOT assay can detect responses
of fewer cells and thus is more sensitive.
The process that led to cPR3138169-specific T cells, B cells,
and antibodies required degradation of a complementary
PR3 protein followed by the display of peptides by HLA
class II molecules on the B-cell surface to T-helper cells.
Genotyping HLA alleles of patients revealed that DRB1*15 is
overrepresented in this group, and furthermore, DRB1*15
molecules are predicted to bind cPR3138169 peptide with
high affinity (HLA Ligand/Motif Database). The HLA-DR2
(which includes DRB1*1501, DRB1*1502, DRB1*1601, and
DRB1*1602) allele group has been associated with ANCA
vasculitides in the past.21–24 Moreover, patients with DR2
were more likely to have persistently positive ANCA. HLA-
DR2 has been associated also with multiple sclerosis,25 anti-
GBM disease,26 and other chronic granulomatous diseases
such as sarcoidosis27 and leprosy.28 An interesting case study
reported a young boy homozygous for HLA-DR2 who
developed anti-GBM disease coincident with ulcerative
colitis.29 It was proposed that the patient’s homozygosity at
HLA-DR2 was a predisposing factor for developing both
diseases. We identified three patients who typed as DRB1*15
homozygosis and all three tested positive for cPR3138169
peptide-specific T cells. The HLA-DR4 (DRB1*0401 and
0
1
2
3
4
Stimulant responsiveness 
(T cells of PR3-ANCA patients)
cPR3 peptide
Sense peptide
Premixed cPR3 + sense
Stimulants
P = 0.006*
P = 0.26
TT, DT, Candida mix
KLH peptide
IF
N
-
γ-
se
cr
e
tio
n 
(m
ea
n f
o
ld
-
ch
an
ge
)
Figure 3 | Complex of cPR3 peptide with sense peptide did not
enhance T-cell responsiveness. Responsiveness was measured
by ELISPOT analysis of IFN-g-secreting cells. Results are shown as
mean fold change as compared with mock control. Positive T-cell
response to recall antigens (mixture containing tetanus toxoid
(TT), diphtheria toxin (DT), and Candida) and non-responsiveness
to KLH indicates responding cells are memory cells versus naive
cells.
Table 2 | Analysis of individuals with positive T-cell responses
Analytical measure Stimulants Patients % responders Healthy controls % responders Statistical significance
Proliferation
cPR3138–169 54% (7 of 13) 8% (1 of 13) P=0.03
Sense PR3138–169 17% (2 of 12) 8% (1 of 13) P=0.60
HI-PR3 31% (4 of 13) 8% (1 of 13) P=0.30
IFN-g secretion
cPR3138–169 52% (13 of 25) 4% (1 of 24) P=0.0003
Sense PR3138–169 20% (5 of 25) 0% (0 of 23) P=0.051
HI-PR3 38% (5 of 13) 0% (0 of 12) P=0.040
IFN-g, interferon-g.
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DRB1*0404) allele group has also been reported to have some
associations with Wegener’s vasculitis.22,30 What is particularly
interesting about DR4 in our studies was that three of five
patients who were negative for responses to cPR3138169 peptide
were the DRB1*04 allele group and two of these have sinus-
limited disease (the only two in the study). A number of other
positive and negative associations with HLA genes have been
reported in systemic vasculitis but what is clear is that there is
yet to be a consensus of a consistent allelic association.31–33
A limitation when studying human T cells is that the only
available sample is peripheral blood cells, unlike animal
studies where spleens and lymph nodes are available. Using
circulating cells, we found that the number of spots in the
ELISPOT assay were less than published animal studies using
spleens. Others report similarly low numbers of spots from
human peripheral cells and propose this is expected for low-
frequency reactive cells.34 These are not unexpected as
memory cells are thought to primarily reside in the spleen
and peripheral lymphoid tissue, with low numbers of cells
found in the circulation. Our efforts to expand the T cells in
culture to increase the number of spots were unsuccessful.
What is comforting is the degree of concordance between
the proliferation studies and the ELISPOT assay with
repetitive patient samplings. Even with these limitations, we
Table 3 | Analysis of overlapping fragments of cPR3138–169 to screen for potential superantigen characteristics
Spot number cPR3138–153 (Fragment 1)a Spot number cPR3146–161 (Fragment 2)a Spot number cPR3154–169 (Fragment 3)a
Patients
B 1.55 1.15 2.65
T 2.41 3.00 4.41
V 2.56 1.00 3.00
R 1.90 1.90 2.50
A 2.50 2.50 5.10
U 0.90 1.70 2.10
P 0.50 0.43 1.18
O 3.68 3.68 3.08
J 1.67 4.27 2.71
D 3.30 2.30 1.90
Q 6.27 3.91 5.73
C 6.80 1.50 2.25
Controls
H-A 0.72 0.04 0.74
H-B 0.31 0.92 1.38
H-C 0.65 0.45 0.65
H-D 0.29 0.77 0.51
H-E 1.41 1.14 1.68
H-F 0.68 1.13 0.92
H-G 1.25 0.69 0.13
H-H 0.61 0.96 0.76
H-I 0.12 0.12 0.36
H-J 4.40 0.27 1.60
H-K 1.05 1.26 2.32
H-L 0.50 1.40 1.60
cPR3, complementary proteinase 3; ELISPOT, enzyme-linked immunospot assay.
cPR3138–169: DLGWGVVGTHAAPAHGQALGAVGHWLVLLWQL.
Fragment 1: DLGWGVVGTHAAPAHG.
Fragment 2: THAAPAHGQALGAVGH.
Fragment 3: QALGAVGHWLVLLWQL.
aThe ELISPOT data are expressed as positive spots of treated wells minus spots on untreated wells.
Table 4 | Comparison of HLA-DRB1 allele frequencies of patients with a population frequency database
Locus Allele group Alleles observed Observed frequency Expected frequency P-value
DRB1 *01 5 0.104 0.128 0.82
*03 8 0.167 0.110 0.24
*04 7 0.146 0.159 0.96
*07 7 0.146 0.145 1.00
*10 1 0.021 0.014 0.53
*11 4 0.083 0.103 0.81
*12 1 0.021 0.010 0.41
*13 2 0.042 0.121 0.15
*14 2 0.042 0.045 1.00
*15 11 0.229 0.093 0.0061*
HLA, human leukocyte antigen.
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successfully demonstrated a strong statistically significant
response in patients compared with healthy controls.
A topic for discussion is why T cells specific for the PR3
autoantigen have been difficult to find at significant levels.
Clayton and Savage designed a system to determine whether
PR3-specific B cells require T cell help to produce antibodies
using peripheral blood lymphocytes culture system. Their
conclusions were that B cells from patients produce PR3
antibodies through a T-cell-independent pathway or through
some nonspecific B-cell stimulation.35 Nonetheless, PR3-
specific T cells are identifiable. Consider for a moment that
anti-idiotypic antibody processes are involved in the genera-
tion of PR3-specific antibodies. This possibility was sup-
ported when mice immunized with cPR3105201 peptide
developed not only anti-cPR3105201 antibodies but also
antibodies that reacted with human-native PR3. These mouse
anti-human PR3 antibodies produced a cytoplasmic-staining
pattern on human neutrophils identical to that produced by
patients’ PR3-ANCA. Thus, in these mice, the derivation of
the anti-human PR3-reactive antibody must have occurred
through an anti-idiotypic response incited by human-specific
complementary protein.1 The anti-idiotypic process is
initiated with a T-cell and B-cell response against a PR3
complementary protein. Antibodies can regulate each other
by suppressing or augmenting the immune reaction in a
manner that would perpetuate autoimmune disease.36–38 An
antibody is immunogenic by virtue of its non-germline-
encoded antigen-binding site. B cells are known to sponta-
neously display endogenous V region peptides on their HLA
class II molecules and activate CD4þ T cells.39,40 Display of
immunoglobulin-derived peptides (idiotopes) on APC HLA
II molecules can occur by several routes. Monocytes and
dendritic cells phagocytize antigen–antibody complexes
bound to surface Fc receptors, and they directly phagocytize
soluble antibodies through routine environmental sampling.
Host antibodies are then degraded and loaded onto HLA II
molecules and displayed on the APC surface in a manner
similar to foreign antigens.41 Alternatively, B cells endocytose
antigens that ligate to surface immunoglobulin (the B-cell
receptor) and process these proteins for display on HLA II
molecules.42–44 How can this information be incorporated into
Table 5 | HLA II alleles predicted to recognize cPR3 peptide
amino acid sequences, based on the immune epitope and
analysis resource database
Locus Allele group Sequence aPredicted affinity IC50 (nM)
DRB1 *0101 WGVVGTHAA 7.0
PAHGQALGA 57.0
WGTHAAPA 83.1
THAAPAHGQ 104.6
GTHAAPAHG 114.6
GQALGAVGH 142.1
*0301 VGHWLVLLW 606.7
*0401 WGVVGTHAA 61,341.5
GHWLVLWQ 146.5
*0701 VGTHAAPAH 1.2
GAVGHWLVL 101.6
QALGAVGHW 466.5
LGAVGHWLV 1253.0
*10 Not available
*1101 LGWGVVGTH 461.5
VGHWLVLLW 2056.4
*12 Not available
*1302 GTHAAPAHG 226.7
GWGVVGTHA 282.2
ALGAVGHWL 410.7
WGVVGTHAA 486.3
*14 Not available
*1501 HGQALGAVG 7.3
HWLVLLWQL 189.8
AVGHWLVLL 243.6
LGWGVVGTH 913.4
cPR3, complementary proteinase 3; HLA, human leukocyte antigen.
cPR3138–169: DLGWGVVGTHAAPAHGQALGAVGHWLVLLWQL.
Fragment 1: DLGWGVVGTHAAPAHG.
Fragment 2: THAAPAHGQALGAVGH.
Fragment 3: QALGAVGHWLVLLWQL.
aInterpretation of predicted affinities: IC50 valueso50=high affinity; IC50 values
o500=intermediate affinity; IC50 valueso5000=low affinity. No known T-cell
epitope has an IC50 value.
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understanding PR3-ANCA generation? Experimental evidence
indicates that animals immunized with human complemen-
tary PR3 protein not only develop antibodies reactive with the
immunogen, but also the development of human-specific PR3
antibodies. That has been observed in mice,1 rabbits, and
chickens (unpublished data). Similarly, a research group that
studies La/sodium chloride-sodium citratein buffer (SSB)-
specific autoantibodies associated with Sjogren’s syndrome and
systemic lupus erythematosus found that mice immunized
with the autoantigen’s complementary peptide counterpart
elicited antibodies against the immunogen and anti-idiotypic
antibodies that reacted with the sense autoantigen.45 It has
been demonstrated in multiple autoimmunity animal models
that anti-idiotypes, raised against autoantibodies, induced
anti-anti-idiotypes that possessed characteristics of the initial
autoantibodies and caused disease after immunization.46,47
A crucial question is the source of the actual complementary
PR3 proteins that triggered the immunological responses
described here. Ongoing studies are addressing this by probing
for proteins from patient material that react with our
antibodies from rabbits immunized with complementary
peptides. The possibilities remain that it could be carried in
by a microbe with proteins homologous to the complementary
protein48,49 or that patients aberrantly transcribe and translate
it.1 Somewhat encouraging, we have detected anti-sense
transcripts in patients using an anti-sense-specific primer for
the reverse transcriptase reaction and PCR.1 Whether these
transcripts are—or even can be—translated is unclear, although
there are reports of translated anti-sense transcripts.50
A recent review proposed that ‘complementary proteins,
which occur naturally, or result from cellular dysfunction,
might be more common than recognized currently. This
implies that the role of complementary proteins in
autoimmunity merits increasing investigation.’51 Under-
standing when and how complementary proteins initiate
autoimmune disease will depend on discovering where these
proteins come from. Nevertheless, there is enough evidence
to warrant a closer look.
MATERIALS AND METHODS
Patients
All subjects gave written informed consent and participated
in the study according to the guidelines of the UNC Institutional
Review Board (IRB no. 97-MED-44). Patients enrolled in the
study with PR3-ANCA disease (n¼ 30) included 11 females and 19
males; mean age of 50.3 years (26–79 years); 3 blacks, 25 Caucasians,
and 2 others (Table 1). Mean of PR3-ANCA titers across samples
was 53.9 (range: 3.2–170.0). Healthy controls were recruited
on site for blood donations (n¼ 34). The disease control group of
seven MPO-ANCA patients included five females and two males,
mean age of 45 years (21–65 years), 1 black, 5 Caucasians,
and 1 Asian. Limits on the amount of blood obtainable per
donation required that the different methodologies in this study be
done in tandem. Thirteen of 30 patients donated blood more
than once during the study’s 2-year period. Studies for anti-cPR3
antibody reactivity required the use of banked sera samples.
Healthy control sera were from approved kidney transplant donors
(n¼ 12).
Proteins and synthetic peptides
Recombinant cPR3105201 protein was produced as previously
described:1 sequence: DAGLAARDESANVMWPAEEGDHGDIELLQ
DLGWGVVGTHAAPAHGQALGAVGHWLVLLWQLDCGDGGTEV
GWAAQLDEENVVQFVLRVVVVQKHLSHREVLLGGLLRPHVVGS
EHHVHQALGYVPQAVRGRQHEAG.
Synthetic peptides from Alpha Diagnostic (San Antonio, TX,
USA) were included as follows:
cPR3138169: N-DLGWGVVGTHAAPAHGQALGAVGHWLVLL
WQL-C (32 aa)
Fragment 1—cPR3138153: N-DLGWGVVGTHAAPAHG-C (16 aa)
Fragment 2—cPR3146161: N-THAAPAHGQALGAVGH-C (16 aa)
Fragment 3—cPR3154169: N-QALGAVGHWLVLLWQL-C (16 aa)
Sense-PR3138169: N-QLPQQDQPVPHGTQCLAMGWGRVGA
HDPPAQV-C (32 aa)
Scrambled peptide: N-LWAGDWVALGLGAWLAGLHVHAQTP
HVQVGGL-C (32 aa)
Native PR3 (Wieslab AB, Lund, Sweden) was passed over
an Extracti-Gel AffinityPak detergent-removing column (Pierce,
Rockford, IL, USA) and heat-inactivated (1001C/10 min)12 to
linearize the protein.9
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Figure 5 | Positive T-cell responses to cPR3138–169 peptide were seen in patients who previously had anti-cPR3138–169 antibodies.
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Recall antigen mixture contained tetanus toxoid (2 mg/ml) and
diphtheria toxin (2mg/ml) (List Labs, Campbell, CA, USA), plus
15 mg/ml of Candida (Allermed Lab, San Diego, CA, USA). Other
agents are concavalin A (Con A) (1 mg/ml), phorbol 12-myristate
13-acetate (PMA) (25 ng/ml), and ionomycin (1 mg/ml) (Sigma,
St Louis, MO, USA).
Cell stimulations
Blood was collected into sodium heparin CPT Cell Preparation
tubes (BD Vacutainer, Franklin Lakes, NJ, USA) and peripheral
blood mononuclear cells were isolated per instructions. Stimulants
included peptides (2–25 mg/ml), HI-PR3 (2–10 mg/ml), recall antigen
mixture, and either ConA or PMA plus ionomycin. Peptide-solvent
dimethyl sulfoxide was added to controls.
CFSE assay
Cytoplasmic proteins were fluorescently labeled with CFSE (0.1mm)
for 15 min (Molecular Probes, Eugene, OR, USA). Subsequent
proliferation in the absence of CFSE results in decreased fluorescence
intensity by one-half with each cell division. Cells were cultured at
1 106 cells per ml for 6 days with proteins (10mg/ml) or peptides
(25mg/ml). CD3þ cells were labeled with phycoerythrin (PE) mouse
anti-human CD3 monoclonal antibody (BD PharMingen, San Diego,
CA, USA) and analyzed by FACScan linked to a CELLQuest software
system (Becton Dickinson Immunocytometry Systems, San Jose, CA,
USA). The cell division index (CDI) is based on 5000 CFSEbright
CD3þ cells as previously described.52
CDI ¼
CFSEdim
CFSEbright=5000
 treated
CFSEdim
CFSEbright=5000
 untreated
Enzyme-linked immunospot assay
Cells were plated at 100ml per 2 106 cells per milliliter in triplicate
on MultiScreen 96-Well Filtration Plates (Millipore, Bedford, MA,
USA)—coated with anti-human IFN-g monoclonal antibody
(Pierce). Treatments included peptides (5 mg/ml), HI-PR3
(2mg/ml), recall antigens, and Con A. IFN-g-releasing cells were
detected with biotinylated mouse anti-human IFN-g antibody
(Pierce) (2mg/ml) and streptavidin (Southern Biotech, Birmingham,
AL, USA) and AEC solution, containing 3-amino-9-ethylcarbazole
tablet, N,N-dimethylformamide and hydrogen peroxide (Sigma).
Data were analyzed using ImmunoSpot reader (ImmunoSpot 3
software, version 3.2; Cellular Technology Ltd, Cleveland, OH, USA).
Intracellular cytokine production of CD4þ and CD8þ cells
Cells (0.8 106/ml per well) were cultured with HI-PR3 (10 mg/ml)
or peptides (5mg/ml) for 4 days. PMAþ ionomycin (6 h) was a
positive control. Brefeldin A (Sigma) was added (10 mg/ml) (4 h).
Cells were fixed using FACS Lysing Solution and FACS Permeabiliz-
ing Solution 2 (Becton Dickinson Immunocytometry Systems) and
were labeled with FastImmune anti-human-IFN-g-FITC antibody
(BD PharMingen) and anti-human CD4- or CD8-PerCP-labeled
antibodies (Becton Dickinson Immunocytometry Systems) and
analyzed by FACScan.
HLA typing
Low-resolution HLA-DRB1 and HLA-DQB1 typing was per-
formed by PCR with sequence-specific primers (PCR-SSP) using
the Pel-Freez DRDQ 3T SSP UniTray system (Dynal Biotech, Brown
Deer, WI, USA) as per instructions. Allele frequencies of the general
population were from the Allele Frequency Database (http://
www.allelefrequencies.net/test).18 The Immune Epitope Database
and Analysis Resource (IEDB) (http://www.immuneepitope.org/
home.do) were used for predictions of HLA II alleles that bind cPR3
peptides.
Detection anti-cPR3 antibodies in sera by ELISA
High-binding plates (Coster, Cambridge, MA, USA) were coated
overnight at 4 1C with recombinant cPR3105201 protein (5 mg/ml).
Sera were added (1:100) and reactive antibodies were detected
with alkaline phosphatase-goat anti-human antibody (Chemicon,
Temecula, CA, USA) plus alkaline phosphatase substrate (Bio-Rad,
Hercules, CA, USA) and read on a VersaMax Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA). Values are percentage of
positive control (rabbit anti-his-tag antibody) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) compared with the mean plus 2 s.d.
of healthy controls.
Statistical analysis
The Wilcoxon rank-sum test was used as a nonparametric
alternative to the two-sample t-test for analysis of T-cell responses
rank-sum to compare patients and healthy controls. The Fisher’s
exact test was used for analysis of HLA allelic frequencies among
patients as compared with a US population database of Caucasians
from Bethesda (n¼ 307). An individual homozygous for an allele
was counted as contributing two alleles to that group. A Bonferroni
correction was used since there were multiple comparisons, with
P-values ofo0.005 required for statistical significance. Ranked linear
regression analysis was used to determine associations between
complementary protein responsive T cells and reactive antibodies.
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